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L
ow-density lipoprotein cholesterol (LDL-C) has long been recognized as a risk factor for atherosclerotic cardiovascular disease (ASCVD). Although the current treatment guidelines clearly state that formal global cardiovascular disease (CVD) assessment should be performed in most individuals without established ASCVD, the guidelines do not recommend risk assessment in those with marked elevation of LDL-C levels. 1 Marked elevation in LDL-C is generally defined as ≥190 mg/ dL (mean LDL-C level in US adults is 113 mg/dL 2 ). The risk of coronary heart disease (CHD) is accelerated by 10 to 20 years in men and 20 to 30 years in women with LDL-C levels ≥190 mg/dL. 3 Although the risk of CHD events has been described as 22-fold higher among those with familial hypercholesterolemia-defining mutations (because of a lifetime exposure to elevated LDL-C levels), the future risk of CHD remains 6-fold higher in those with LDL-C ≥190 mg/dL and no familial hypercholesterolemia-related mutations. 4 Statin therapy significantly lowers the risk of ASCVD events in these patients. 5 It is important to note that although the prevalence of heterozygous familial hypercholesterolemia may be 1 in 250, the prevalence of LDL-C ≥190 mg/dL may be as high as 5% to 7% in the general population. 3, 6 Long-term ASCVD risk associated with more moderate elevations in LDL-C levels is not well described, especially among young individuals and those without other major ASCVD risk factors. In this population, 10-year ASCVD risk using current risk assessment tools may be low.
WHAT DOES THIS STUDY SHOW?
The study by Abdullah et al 7 in this issue of Circulation fills this gap. In a group of relatively low-risk individuals (n=36 375) with 10-year ASCVD risk <7.5% (median 1.3% 10-year ASCVD risk) using the Pooled Cohort Risk Equation and without a history of ASCVD or diabetes mellitus at baseline, the association between fasting LDL-C (or non-high-density lipoprotein cholesterol [non-HDL-C]) levels and ASCVD mortality was evaluated over a median follow-up of 26.8 years. Compared with those with LDL-C <100 mg/dL, individuals with LDL-C levels of 160 to 189 mg/dL (hazard ratio [HR], 1.7; 95% CI, 1.4-2.2) and those with LDL-C ≥190 mg/dL (HR, 1.5; 95% CI, 1.2-2.1) had increased risk for CVD mortality. This would roughly equate to mean reductions in years free of CVD death of 4.3 and 3.9, respectively. Similarly, non-HDL-C levels of 160 to 189 mg/dL (HR, 1.3; 95% CI, 1.1-1.6), 190 to 219 mg/dL (HR, 1.8; 95% CI, 1.4-2.2), and ≥220 mg/dL (HR, 1.5; 95% CI, 1.2-2.0) were significantly associated with CVD death compared with non-HDL-C levels <130 mg/dL. Results were qualitatively similar when analyses were restricted to those with 10-year ASCVD risk ≤5% (89% of the cohort).
Several observations can be made from these important analyses in otherwise low-risk individuals. First, even moderately elevated LDL-C levels in the range of 160 to 189 mg/dL over a 27-year follow-up were associated with an increased risk of CVD death, with roughly 4.3 years' reduction in years free of CVD. Second, non-HDL-C levels showed an association with CVD death (and all-cause mortality) that was more robust at even lower levels compared with the corresponding LDL-C levels. This finding is not surprising because non-HDL-C includes the cholesterol content of all atherogenic lipoproteins, including low-density lipoprotein, intermediate-density lipoprotein, very-low-density lipoprotein, lipoprotein(a), and chylomicron remnants. 8 Therefore, non-HDL-C calculation captures the risk associated with both cholesterol-rich lipoproteins and triglyceride-rich remnant lipoproteins. This observation reemphasizes that non-HDL-C is superior to LDL-C in identifying future ASCVD risk.
These results should be interpreted in the context of the limitations of the analyses. No information on baseline or follow-up lipid-lowering therapies was available. Also, age was not adjusted for in the main analyses because of violation of the proportional-hazards assumption. It is quite possible that given such a long follow-up, some would reach a threshold of 7.5% 10-year ASCVD risk because of age or the development of age-dependent risk factors and, therefore, would meet the guideline-recommended risk threshold of 7.5% 10-year ASCVD risk for discussion regarding statin therapy.
WHAT ARE THE IMPLICATIONS OF THE FINDINGS?
First, these analyses indicate that there is no "threshold" at which atherogenic lipoproteins increase ASCVD risk. Even moderate elevations in atherogenic lipoproteins, without other risk factors and with a low 10-year ASCVD risk, are associated with increased long-term risk of CVD mortality and possibly all-cause mortality. This finding raises questions of whether 10-year or lifetime ASCVD risk assessment should be performed first in individuals with LDL-C 160 to 189 mg/dL or whether they should begin lipid-lowering treatments based on long-term risk similar to individuals with LDL-C levels ≥190 mg/dL. As noted in the current analyses, the association between LDL-C levels and CHD mortality (or CVD mortality) was not significant when analyses were truncated at 10 years.
Second, should patients with LDL-C 160 to 189 mg/ dL be treated early? Most primary-prevention trials [9] [10] [11] (Table) included a low-risk population, and some included patients with LDL-C ≥160 mg/dL; however, the baseline age in those trials was higher than the mean of 42 years in the current study. Although treating those with LDL-C 160 to 189 mg/dL but low 10-year ASCVD risk early in life sounds promising, it would lead to treating a much larger number of individuals than the current recommendation of treating those with LDL-C ≥190 mg/dL. For example, individuals with LDL-C 160 to 189 mg/dL comprised 13% of the overall study population. The 2013 American College of Cardiology/American Heart Association cholesterol guideline notes that statin therapy may be considered (class IIb recommendation with level of evidence C) in individuals with LDL-C ≥160 mg/dL who are otherwise not considered for statin therapy based on the statin benefit groups. 1 The current analyses could substantiate updating the level of evidence for this recommendation, which, when combined with clinical trial evidence ( Table) , could support early initiation of statin therapy in at least some of these individuals. At least 2 of these primary-prevention trials 9, 11 (Table) showed benefit in individuals with LDL-C levels ≈160 mg/dL and 10-year ASCVD risk <7.5%. It is unlikely that clinical trials of statin therapy will be performed in a population of this age with few risk factors because of the large sample size and long-term followup required. How, then, should observational data such as found in this study be used for joint decision-making with our patients?
Third, these analyses reemphasize the importance of calculating non-HDL-C. Although the Adult Treatment Panel III guideline recommended non-HDL-C as a secondary treatment target especially among individuals with elevated triglycerides, 12 the 2013 American College of Cardiology/American Heart Association cholesterol guideline did not include non-HDL-C for treatment decisions because trials of statin therapy mostly used LDL-C levels for eligibility. 1 The analyses in the current study show that non-HDL-C levels were associated with CHD and CVD mortality at much lower levels (130-159 mg/dL) than the corresponding LDL-C levels. It is important to note that all recent outcomes trials of PCSK9 inhibitors (most of which included secondaryprevention patients) used both LDL-C and non-HDL-C thresholds for eligibility 13, 14 and could therefore include patients with elevated non-HDL-C levels despite LDL-C levels below the eligibility criterion. Should clinicians use non-HDL-C in addition to LDL-C when making decisions regarding lipid-lowering therapy?
WHAT ARE THE REMAINING GAPS?
Although the authors evaluated elevation of LDL-C and non-HDL-C levels in midlife, there are other clinical circumstances in which LDL-C levels may be elevated but the duration of exposure may not be as long. One example would be perimenopausal elevation of LDL-C. 15 Menopause can lead to elevated LDL-C, which in some cases may approach 160 to 189 mg/dL. Should these women be treated with lipid-lowering therapy? Although these women may have elevated LDL-C levels, their risk may not be as high as individuals in the current analyses because overall risk is likely a combination of the degree of elevation of atherogenic lipoproteins and the duration of exposure (shorter in women with perimenopausal LDL-C elevation). Last, although imaging, especially coronary calcium score, has been shown to stratify risk in intermediate-risk individuals, 16 can imaging be used for risk stratification in individuals with moderate LDL-C elevation? Can therapy be withheld with a coronary calcium score of 0 when LDL-C levels are 160 to 189 mg/dL, especially when one considers the limitations of coronary calcium scores in young individuals? This finding would be important given the considerable number of individuals with LDL-C 160 to 189 mg/dL, the need for lifelong treatment once lipidlowering therapy is started, and possibly a higher risk for statin-associated side effects given the longer duration of therapy.
In conclusion, these analyses solidify the evidence that even moderately elevated atherogenic lipoprotein levels, especially when present over a long-term followup, are associated with an increased risk of CVD death and possibly overall mortality. Adapted from the supplement to the 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease in Adults.
